Zepbound gets new pen

Most people taking Zepbound have been using one disposable pen for one weekly shot. Eli Lilly has now started selling a different device: one KwikPen that holds four weekly doses in a single pen for one patient. (hcplive.com) Zepbound is tirzepatide, a once-weekly prescription injection for adults with obesity, and for some adults with overweight plus a weight-related medical problem. Lilly’s label also says it can be used to treat moderate to severe obstructive sleep apnea in adults with obesity. (zepbound.lilly.com) Tirzepatide works by activating two hormone pathways that help people feel fuller and eat less: glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1. Lilly’s prescribing information describes it as a dual receptor agonist given under the skin once a week. (pi.lilly.com) The device change sounds small, but it changes the routine. Instead of opening a brand-new injector every week, a patient uses the same pen across four weeks and attaches a fresh disposable needle for each shot. (hcplive.com) That is why Lilly had to add a new safety warning in January 2026: never share a Zepbound KwikPen between patients, even if the needle is changed. The updated label also says each injection should use a new needle and the pen should be thrown away 30 days after first use. (pi.lilly.com) The KwikPen comes in all six Zepbound strengths: 2.5 milligrams, 5 milligrams, 7.5 milligrams, 10 milligrams, 12.5 milligrams, and 15 milligrams. Industry coverage of Lilly’s February 23, 2026 launch said the pen became available through LillyDirect Pharmacy with prices starting at $299 a month for 2.5 milligrams and topping out at $449 for the higher doses for self-pay patients. (hcplive.com) (news.iheart.com) Lilly is not just changing packaging. It is also widening the ways patients can get the drug: Ro said on April 2, 2026 that it was launching the recently Food and Drug Administration-approved Zepbound KwikPen nationwide on its platform. (ro.co) The backdrop is a market where demand, insurance gaps, and shortages have pushed drugmakers to rethink distribution. Lilly has been steering cash-pay patients toward direct channels like LillyDirect, and the KwikPen fits that strategy because one pen can cover a full month instead of four separate injector bodies. (pharmaceuticalcommerce.com) (hcplive.com) The medicine itself has not changed. What changed is the container, the weekly workflow, and the economics around getting a month of treatment into a patient’s hands with fewer pieces of plastic and fewer separate pens. (pi.lilly.com) (hcplive.com)